Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 11 studies | 28% ± 11% | |
astrocyte | 10 studies | 29% ± 12% | |
oligodendrocyte precursor cell | 8 studies | 27% ± 11% | |
glutamatergic neuron | 7 studies | 44% ± 25% | |
GABAergic neuron | 7 studies | 39% ± 20% | |
interneuron | 6 studies | 36% ± 20% | |
macrophage | 6 studies | 25% ± 7% | |
oligodendrocyte | 6 studies | 27% ± 7% | |
neuron | 5 studies | 33% ± 10% | |
smooth muscle cell | 5 studies | 18% ± 1% | |
epithelial cell | 5 studies | 28% ± 8% | |
fibroblast | 5 studies | 21% ± 6% | |
microglial cell | 4 studies | 29% ± 7% | |
type I pneumocyte | 4 studies | 22% ± 7% | |
hematopoietic precursor cell | 3 studies | 19% ± 3% | |
GABAergic interneuron | 3 studies | 23% ± 8% | |
granule cell | 3 studies | 21% ± 1% | |
retinal cone cell | 3 studies | 20% ± 5% | |
abnormal cell | 3 studies | 35% ± 10% | |
pericyte | 3 studies | 23% ± 5% | |
transit amplifying cell | 3 studies | 41% ± 22% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4516.88 | 1445 / 1445 | 100% | 40.24 | 183 / 183 |
intestine | 100% | 4408.40 | 966 / 966 | 100% | 24.06 | 527 / 527 |
lung | 100% | 4906.09 | 578 / 578 | 100% | 32.69 | 1155 / 1155 |
ovary | 100% | 4963.96 | 180 / 180 | 100% | 32.63 | 430 / 430 |
skin | 100% | 5578.31 | 1809 / 1809 | 100% | 43.59 | 472 / 472 |
brain | 100% | 4832.21 | 2640 / 2642 | 100% | 48.52 | 705 / 705 |
breast | 100% | 4741.88 | 459 / 459 | 100% | 41.14 | 1117 / 1118 |
stomach | 100% | 3478.72 | 359 / 359 | 100% | 27.45 | 285 / 286 |
uterus | 100% | 5598.75 | 170 / 170 | 100% | 35.90 | 457 / 459 |
prostate | 100% | 4353.10 | 245 / 245 | 99% | 20.12 | 498 / 502 |
thymus | 100% | 5868.74 | 653 / 653 | 99% | 23.96 | 600 / 605 |
bladder | 100% | 4645.00 | 21 / 21 | 99% | 25.02 | 498 / 504 |
pancreas | 100% | 2779.75 | 327 / 328 | 99% | 19.28 | 176 / 178 |
liver | 100% | 2381.81 | 226 / 226 | 96% | 17.92 | 391 / 406 |
kidney | 100% | 3115.85 | 89 / 89 | 95% | 18.79 | 859 / 901 |
adrenal gland | 100% | 4475.63 | 258 / 258 | 94% | 21.94 | 216 / 230 |
adipose | 100% | 4589.75 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5264.70 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 21.94 | 29 / 29 |
spleen | 100% | 4299.10 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 33.60 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.12 | 1 / 1 |
muscle | 100% | 2885.38 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2715.23 | 854 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 25.01 | 79 / 80 |
peripheral blood | 78% | 2417.21 | 728 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006606 | Biological process | protein import into nucleus |
GO_0031144 | Biological process | proteasome localization |
GO_0005829 | Cellular component | cytosol |
GO_0005635 | Cellular component | nuclear envelope |
GO_0016020 | Cellular component | membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0061608 | Molecular function | nuclear import signal receptor activity |
GO_0005515 | Molecular function | protein binding |
GO_0140713 | Molecular function | histone chaperone activity |
GO_0031267 | Molecular function | small GTPase binding |
GO_0042393 | Molecular function | histone binding |
Gene name | IPO9 |
Protein name | Importin-9 (Imp9) (Ran-binding protein 9) (RanBP9) Importin 9 |
Synonyms | KIAA1192 RANBP9 IMP9 HSPC273 |
Description | FUNCTION: Nuclear transport receptor that mediates nuclear import of proteins, such as histones, proteasome and actin . Serves as receptor for nuclear localization signals (NLS) in cargo substrates . Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism . At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran . The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus . Mediates the import of pre-assembled proteasomes into the nucleus; AKIRIN2 acts as a molecular bridge between IPO9 and the proteasome complex . Mediates the nuclear import of histones H2A, H2B, H4 and H4 . In addition to nuclear import, also acts as a chaperone for histones by preventing inappropriate non-nucleosomal interactions . Mediates the nuclear import of actin (By similarity). . |
Accessions | ENST00000456707.1 Q5SVH5 Q96P70 ENST00000361565.9 |